About OXB
OXB is a company based in Oxford (United Kingdom) founded in 1995 by Neill Mackenzie. It operates as a Managed Services, and Professional Services. The company has 861 employees as of December 31, 2024. OXB has completed 4 acquisitions, including ABL, ABL Europe and Homology Medicines. OXB offers products and services including LentiVector™ Platform, inAAVate™ Platform, and CDMO Services. OXB operates in a competitive market with competitors including Orgenesis, Ori Biotech, MaSTherCell, Cognate Bioservices and Cell-Easy, among others.
- Headquarter Oxford, United Kingdom
- Employees 861 as on 31 Dec, 2024
- Founders Neill Mackenzie
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Oxford Biomedica Plc
-
Annual Revenue
$161.38 M (USD)43.84as on Dec 31, 2024
-
Net Profit
$-54.11 M (USD)72.58as on Dec 31, 2024
-
EBITDA
$-29.18 M (USD)61.28as on Dec 31, 2024
-
Latest Funding Round
$81.34 M (USD), Post-IPO
Aug 15, 2025
-
Investors
Briarwood Chase Management
& 1 more
-
Employee Count
861
as on Dec 31, 2024
-
Investments & Acquisitions
ABL
& 3 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of OXB
OXB is a publicly listed company on the LSE with ticker symbol OXB in UK, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of OXB
OXB offers a comprehensive portfolio of products and services, including LentiVector™ Platform, inAAVate™ Platform, and CDMO Services. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Innovative lentiviral gene delivery technology is commercially approved.
Proven AAV vector development ensures high-quality clinical products.
End-to-end viral vector manufacturing supports cell therapy clients.
Unlock access to complete
Unlock access to complete
Software Development Team
37 people
Leadership Team
27 people
Product Management Team
21 people
Senior Team
20 people
Scientist Team
7 people
Legal and Compliance
6 people
Sales and Marketing
6 people
Operations Team
6 people
Unlock access to complete
Funding Insights of OXB
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $81.3M
- First Round First Round
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2025 | Amount | Post-IPO - OXB | Valuation |
investors |
|
| Jan, 2025 | Amount | Post-IPO - OXB | Valuation |
investors |
|
| Sep, 2021 | Amount | Post-IPO - OXB | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in OXB
OXB has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Briarwood Chase Management and Novo Holdings. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Founded Year | Domain | Location | |
|
Briarwood Chase Management is focused on long-term global investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by OXB
OXB has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include ABL, ABL Europe and Homology Medicines. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of gene therapies for rare genetic diseases
|
2015 | ||||
|
Biotechnology products are developed to enhance immune responses against diseases.
|
2004 | ||||
|
Contract research and manufacturing for biologics and vaccines are provided.
|
1961 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - OXB
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Oxb Comparisons
Competitors of OXB
OXB operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Orgenesis, Ori Biotech, MaSTherCell, Cognate Bioservices and Cell-Easy, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Cell and gene therapies for multiple disorders are developed.
|
|
| domain | founded_year | HQ Location |
Software development services are provided for the biopharma sector.
|
|
| domain | founded_year | HQ Location |
Services for cell therapy development and manufacturing are provided.
|
|
| domain | founded_year | HQ Location |
Development and manufacturing services for cell-based therapies are provided.
|
|
| domain | founded_year | HQ Location |
Stem cell-based therapy services for research solutions are provided.
|
|
| domain | founded_year | HQ Location |
A biotechnology company focused on anti-aging therapeutics development.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Oxb
Frequently Asked Questions about OXB
When was OXB founded?
OXB was founded in 1995 and raised its 1st funding round 24 years after it was founded.
Where is OXB located?
OXB is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Who is the current CEO of OXB?
Tim Kelly is the current CEO of OXB.
How many employees does OXB have?
As of Dec 31, 2024, the latest employee count at OXB is 861.
What is the annual revenue of OXB?
Annual revenue of OXB is $161.38M as on Dec 31, 2024.
What does OXB do?
OXB is established as a global leader in cell and gene therapy contract development and manufacturing (CDMO), with over 30 years of expertise in viral vectors. Services are provided to innovative pharmaceutical and biotechnology companies, covering lentivirus, AAV, adenovirus, and other vector types. End-to-end capabilities are offered, from early-stage development to commercialization, supported by robust quality systems and regulatory knowledge. Operations span multiple sectors within healthcare, focusing on enabling life-changing therapies for patients worldwide through advanced manufacturing and development solutions.
Who are the top competitors of OXB?
OXB's top competitors include Ori Biotech, MaSTherCell and Genflow Biosciences.
What products or services does OXB offer?
OXB offers LentiVector™ Platform, inAAVate™ Platform, and CDMO Services.
Is OXB publicly traded?
Yes, OXB is publicly traded on LSE under the ticker symbol OXB.
How many acquisitions has OXB made?
OXB has made 4 acquisitions, including ABL, ABL Europe, and Homology Medicines.
Who are OXB's investors?
OXB has 2 investors. Key investors include Briarwood Chase Management, and Novo Holdings.
What is OXB's ticker symbol?
The ticker symbol of OXB is OXB on LSE.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.